Literature DB >> 2308583

Studies on the effect of ketoconazole on the fusion of L6 myoblasts.

S Wayne1, J C Jamieson, M A Spearman, J A Wright.   

Abstract

The effect of ketoconazole on the fusion of L6 myoblasts was studied. Ketoconazole was a potent inhibitor of myoblast fusion at concentrations as low as 0.1 microM, but fusion was restored when the inhibitor was removed. The inhibitor resulted in decreased binding of conA and WGA to cell surface oligosaccharides showing that it was inhibiting N-linked cell surface glycoproteins. Inhibition of fusion by ketoconazole was accompanied by reduced creatine phosphokinase activities showing that it is affecting biochemical differentiation. Incorporation of labelled mannose from GDP-mannose into lipid-sugar and lipid-oligosaccharide complexes involved in the synthesis of N-linked oligosaccharides was also inhibited by ketoconazole, but the inhibition was reversed by addition of exogenous dolichol phosphate to the incorporation mixture. The main conclusion from these studies was that ketoconazole inhibited fusion of L6 myoblasts by affecting the synthesis of dolichol-phosphate required for the synthesis of lipid-oligosaccharides needed for the synthesis of fusogenic cell surface N-linked glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308583     DOI: 10.1007/bf00218131

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  14 in total

1.  Tandem events in myoblast fusion.

Authors:  K A Knudsen; A F Horwitz
Journal:  Dev Biol       Date:  1977-07-15       Impact factor: 3.582

2.  Differentiation defective mutants of skeletal myoblasts altered in a gelatin-binding glycoprotein.

Authors:  G A Cates; D Nandan; A M Brickenden; B D Sanwal
Journal:  Biochem Cell Biol       Date:  1987-09       Impact factor: 3.626

3.  Studies on glycoprotein biosynthesis in concanavalin A-resistant cell lines. Defective formation of mannose-linked lipid intermediates.

Authors:  J A Wright; J C Jamieson; H Ceri
Journal:  Exp Cell Res       Date:  1979-06       Impact factor: 3.905

4.  A correlation between loss of fusion potential and defective formation of mannose-linked lipid intermediates in independent concanavalin A-resistant myoblast cell lines.

Authors:  C L Parfett; J C Jamieson; J A Wright
Journal:  Exp Cell Res       Date:  1981-11       Impact factor: 3.905

5.  Mechanistic studies of lanosterol C-32 demethylation. Conditions which promote oxysterol intermediate accumulation during the demethylation process.

Authors:  J M Trzaskos; R T Fischer; M F Favata
Journal:  J Biol Chem       Date:  1986-12-25       Impact factor: 5.157

6.  Effects of ketoconazole on cholesterol synthesis.

Authors:  F B Kraemer; S D Spilman
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

7.  A method for the direct demonstration of the lectin-binding components of the human erythrocyte membrane.

Authors:  M J Tanner; D J Anstee
Journal:  Biochem J       Date:  1976-02-01       Impact factor: 3.857

8.  Changes in cell surface glycoproteins on non-differentiating L6 rat myoblasts selected for resistance to concanavalin A.

Authors:  C L Parfett; J C Jamieson; J A Wright
Journal:  Exp Cell Res       Date:  1983-04-01       Impact factor: 3.905

9.  Studies on the effect of glycoprotein processing inhibitors on fusion of L6 myoblast cell lines.

Authors:  M A Spearman; J C Jamieson; J A Wright
Journal:  Exp Cell Res       Date:  1987-01       Impact factor: 3.905

10.  Inhibition of myoblast fusion by the glucosidase inhibitor N-methyl-1-deoxynojirimycin, but not by the mannosidase inhibitor 1-deoxymannojirimycin.

Authors:  P C Holland; A Herscovics
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

View more
  1 in total

1.  Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts.

Authors:  R S Belo; J C Jamieson; J A Wright
Journal:  Mol Cell Biochem       Date:  1993-09-22       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.